Apimeds Pharmaceuticals US, Inc. 10-Q filing
Filed 2025-11-12 · Report date 2025-09-30 · 2025
Filing metadata
- Accession number
- 0001213900-25-109280
- Form type
- 10-Q
- CIK
- 0001894525
- Primary document
- https://www.sec.gov/Archives/edgar/data/1894525/000121390025109280/ea0264386-10q_apimeds.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Apimeds Pharmaceuticals US, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-4.9M | - | - |
| Net Income | $-4.8M | - | - |
| Eps Basic | -0.47 | - | - |
| Eps Diluted | -0.47 | - | - |
| Cash And Equivalents | $7.0M | - | - |
| Total Assets | $9.3M | - | - |
| Total Liabilities | $1.1M | - | - |
| Shareholders Equity | $8.2M | - | - |
| Operating Cash Flow | $-5.1M | - | - |
| Capital Expenditures | $35,909 | - | - |